Verastem, Inc.
VSTM · XNASCIK 1526119fmd_1SYDK419ZWK32WG1CZXXFDV1J0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2026, 63 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 27 | 17 | 89 | 2 | 3 | – | 10 | 31 |
| Cost of revenue | – | – | 0 | – | – | – | – | – | – | – |
| Gross profit | – | – | 27 | – | – | – | – | – | – | – |
| Research and development | 20 | 46 | 44 | 46 | 41 | 39 | 51 | 61 | 81 | 115 |
| Selling, general and administrative | 17 | 21 | 77 | 101 | 63 | 24 | 25 | 31 | 44 | 81 |
| Total operating expenses | 37 | 68 | 122 | – | – | – | – | – | – | – |
| Operating income | (37) | (68) | (95) | (132) | (49) | (61) | (73) | (92) | (115) | (170) |
| Interest expense | – | 1 | 6 | 21 | 16 | 10 | 2 | 4 | 5 | 1 |
| Interest and investment income | 1 | 1 | 3 | 4 | 1 | 0 | 1 | 6 | 4 | 4 |
| Other non-operating income (expense) | – | – | 26 | (1) | (1) | – | 0 | (0) | (0) | (0) |
| Income before taxes | – | – | (72) | (149) | (68) | (71) | (74) | (87) | (130) | (209) |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 | – | 0 | – |
| Net income from continuing operations | – | – | (72) | (149) | (68) | (71) | (74) | – | (131) | – |
| Net income | (36) | (68) | (72) | (149) | (68) | (71) | (74) | (87) | (131) | (209) |
| Net income to common shareholders | (36) | (68) | (95) | (149) | (68) | – | – | – | – | – |